COMMUNIQUÉS West-GlobeNewswire

NeOnc' Phase 2 Data Could Put Cancer on the Ropes
08/09/2026
NeOnc Looking to Turn Phase 2 Win into FDA Action DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ: NTHI) , the Phase 2a question has been answered. Now comes the [...]
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
08/09/2026
First-of-Its-Kind Integration Connects TrakStar and AdvancedMD, Delivering TMS Care Across Clinical, Operational, and Billing Workflows MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), [...]
Bone Biologics Expands Trial Sites
08/09/2026
Addition of three sites strengthens expectation to complete enrollment by year-end 2026 BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “ [...]
Sparrow Pharmaceuticals Appoints George Eldridge as Chief Financial Officer
08/09/2026
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the appointment of George Eldridge as Chief Financial Officer. Mr. Eldridge brings [...]
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
08/09/2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present [...]
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“ Optimi ” or the “ Company ”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic [...]
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
08/09/2026
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin [...]
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
08/09/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized [...]
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
08/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to [...]
Merakris Therapeutics Launches Patent-Pending AmnioSurge™ With 360 Medical, Opening New Surgical Revenue Channel
08/09/2026
Procedure-specific biologic technology combines surgeon training, scalable tissue processing and a capital-efficient commercialization model RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Merakris [...]
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
08/09/2026
AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients [...]
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for [...]
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
08/09/2026
Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology [...]
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
08/09/2026
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global [...]
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
08/09/2026
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
08/09/2026
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a [...]
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
08/09/2026
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive [...]
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
08/09/2026
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics , a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board [...]
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
08/09/2026
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, [...]

Pages